SLC7A11 and neoplasm: Studies demonstrate that p53 variants carrying triple lysine site mutations (3KR), despite losing traditional tumor‐suppressive functions, maintain ferroptosis‐mediated tumor suppression by activating the ALOX12 (arachidonate 12‐LOX) signaling pathway and significantly inhibiting SLC7A11 cystine transport system activity [401].